Suppr超能文献

术后化疗对有危险因素的 pT1bN0 和 pT2N0 胃癌患者的疗效:一项国际双中心分析。

The Effectiveness of Postoperative Chemotherapy on pT1bN0 and pT2N0 Gastric Cancer Patients with Risk Factors: An International Dual-Center Analysis.

机构信息

Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China.

Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

出版信息

Yonsei Med J. 2021 Feb;62(2):109-117. doi: 10.3349/ymj.2021.62.2.109.

Abstract

PURPOSE

This study aimed to investigate the effectiveness of postoperative chemotherapy in pT1bN0 and pT2N0 gastric cancer patients with high risk factors.

MATERIALS AND METHODS

Clinicopathological data of gastric cancer patients, who had undergone gastrectomy in high volume centers in Korea and China and were finally diagnosed with pT1bN0 and pT2N0 between 2006 and 2010, were analyzed retrospectively. Survival analyses stratified by risk factors and multivariable analyses were performed.

RESULTS

A total of 1509 patients were enrolled, with 41 (2.7%) patients receiving adjuvant chemotherapy after gastrectomy and 1468 (97.3%) patients undergoing surgery alone. The adjuvant chemotherapy group showed higher percentages of tumor with maximal diameter >3 cm (51.2% vs. 25.8%), poor differentiation (68.3% vs. 49.8%), and less harvested lymph nodes (17.1% vs. 5.2%) compared to the surgery alone group. The overall survival rates were 95.1% in the adjuvant chemotherapy group and 93.3% in the surgery alone group, without significant difference. In multivariable analysis, age was found to be an independent prognostic factor. However, there were no difference in the overall survival between patients with risk factors and those without risk factors, even in terms of age. Meanwhile, patients with more than two risk factors who received chemotherapy showed better survival trend, especially for pT2N0 patients, compared to the surgery alone group, although no significant differences were observed.

CONCLUSION

In pT1bN0 and pT2N0 patients, age was found to be an independent prognostic factor. However, adjuvant chemotherapy seemed to be unnecessary, while postoperative chemotherapy might offer survival benefits to pT2N0 patients with more than two risk factors.

摘要

目的

本研究旨在探讨高风险因素的 pT1bN0 和 pT2N0 胃癌患者术后化疗的疗效。

材料与方法

回顾性分析了 2006 年至 2010 年间在韩国和中国的大容量中心接受胃切除术且最终诊断为 pT1bN0 和 pT2N0 的胃癌患者的临床病理资料。对风险因素分层的生存分析和多变量分析。

结果

共纳入 1509 例患者,其中 41 例(2.7%)患者在胃切除术后接受辅助化疗,1468 例(97.3%)患者仅行手术治疗。与单独手术组相比,辅助化疗组肿瘤最大直径>3cm(51.2%比 25.8%)、分化差(68.3%比 49.8%)和淋巴结清扫较少(17.1%比 5.2%)的比例更高。辅助化疗组和单独手术组的总生存率分别为 95.1%和 93.3%,差异无统计学意义。多变量分析发现,年龄是独立的预后因素。然而,有风险因素和无风险因素的患者之间的总生存率没有差异,即使在年龄方面也是如此。同时,接受化疗的有两个以上危险因素的患者,尤其是 pT2N0 患者,与单独手术组相比,生存趋势更好,尽管无显著差异。

结论

在 pT1bN0 和 pT2N0 患者中,年龄是独立的预后因素。然而,辅助化疗似乎没有必要,而术后化疗可能为有两个以上危险因素的 pT2N0 患者带来生存获益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c08b/7859688/48ee90004bd0/ymj-62-109-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验